MCID: NNL001
MIFTS: 34

Non-Langerhans-Cell Histiocytosis

Categories: Immune diseases, Rare diseases

Aliases & Classifications for Non-Langerhans-Cell Histiocytosis

MalaCards integrated aliases for Non-Langerhans-Cell Histiocytosis:

Name: Non-Langerhans-Cell Histiocytosis 12 53 15
Histiocytosis, Non-Langerhans-Cell 76 53 44 73

Classifications:



External Ids:

Disease Ontology 12 DOID:4330
MeSH 44 D015616
UMLS 73 C0019624

Summaries for Non-Langerhans-Cell Histiocytosis

MalaCards based summary : Non-Langerhans-Cell Histiocytosis, also known as histiocytosis, non-langerhans-cell, is related to erdheim-chester disease and juvenile xanthogranuloma. An important gene associated with Non-Langerhans-Cell Histiocytosis is CD163 (CD163 Molecule), and among its related pathways/superpathways are Dendritic Cells Developmental Lineage Pathway and Striated Muscle Contraction. The drugs Dexamethasone acetate and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include pituitary, myeloid and smooth muscle, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 76 Non-Langerhans cell histiocytosis refers to a family of histiocytosis characterized by the absence of... more...

Related Diseases for Non-Langerhans-Cell Histiocytosis

Diseases related to Non-Langerhans-Cell Histiocytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 79)
# Related Disease Score Top Affiliating Genes
1 erdheim-chester disease 32.7 BRAF SST
2 juvenile xanthogranuloma 32.2 BRAF DES F13A1 LYZ
3 reticulohistiocytic granuloma 32.1 CD163 CD207 LYZ
4 langerhans cell histiocytosis 30.7 BRAF CD163 CD207 F13A1
5 histiocytosis 30.6 BRAF CD163 CD207 IL1RN
6 fibromatosis 30.3 ACTC1 DES
7 fibroblastic rheumatism 30.0 ACTC1 CD163 DES F13A1
8 histiocytosis, progressive mucinous 11.5
9 lipogranulomatosis 10.5
10 myofibroma 10.2 DES F13A1
11 progressive nodular histiocytosis 10.2 ACTC1 F13A1
12 scleromyxedema 10.2 ACTC1 F13A1
13 ovarian fibrothecoma 10.2 ACTC1 DES
14 cutaneous leiomyosarcoma 10.2 ACTC1 DES
15 leiomyosarcoma 10.2 ACTC1 DES
16 giant cell tumor 10.2 ACTC1 DES
17 botryoid rhabdomyosarcoma 10.1 ACTC1 DES
18 central nervous system sarcoma 10.1 CD163 LYZ
19 spindle cell lipoma 10.1 ACTC1 DES
20 glomangioma 10.1 ACTC1 DES
21 parachordoma 10.1 ACTC1 DES
22 adult xanthogranuloma 10.1 CD163 LYZ
23 ossifying fibromyxoid tumor 10.1 ACTC1 DES
24 epithelioid leiomyosarcoma 10.1 ACTC1 DES
25 benign metastasizing leiomyoma 10.1 ACTC1 DES
26 pulmonary vein stenosis 10.1 ACTC1 DES
27 dermis tumor 10.1 CD163 LYZ
28 perivascular epithelioid cell tumor 10.1 ACTC1 DES
29 congenital fibrosarcoma 10.1 ACTC1 DES
30 ischemic fasciitis 10.1 ACTC1 DES
31 fasciitis 10.1 ACTC1 DES
32 reticulum cell sarcoma 10.1 ACTC1 DES
33 pseudosarcomatous fibromatosis 10.1 ACTC1 DES
34 cavernous sinus meningioma 10.1 CD163 CD207
35 dedifferentiated liposarcoma 10.1 ACTC1 DES
36 glomus tumor 10.1 ACTC1 DES
37 spindle cell sarcoma 10.1 ACTC1 DES
38 alk+ histiocytosis 10.1 CD207 F13A1
39 smooth muscle tumor 10.1 ACTC1 DES
40 langerhans cell sarcoma 10.1 CD163 CD207
41 malignant giant cell tumor of soft parts 10.1 ACTC1 LYZ
42 binswanger's disease 10.1 ACTC1 SST
43 infantile myofibromatosis 10.1 ACTC1 DES
44 chondromyxoid fibroma 10.1 ACTC1 DES
45 kawasaki disease 10.1
46 dermatitis 10.1
47 histiocytoma 10.1
48 rosai-dorfman disease 10.1
49 xanthoma disseminatum 10.1
50 headache 10.1

Graphical network of the top 20 diseases related to Non-Langerhans-Cell Histiocytosis:



Diseases related to Non-Langerhans-Cell Histiocytosis

Symptoms & Phenotypes for Non-Langerhans-Cell Histiocytosis

MGI Mouse Phenotypes related to Non-Langerhans-Cell Histiocytosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.87 ACTC1 BRAF CD163 DES F13A1 IL1RN
2 homeostasis/metabolism MP:0005376 9.76 ACTC1 BRAF CD163 DES F13A1 IL1RN
3 hematopoietic system MP:0005397 9.73 BRAF CD163 CD207 F13A1 IL1RN LYZ
4 mortality/aging MP:0010768 9.5 ACTC1 BRAF DES F13A1 IL1RN LYZ
5 respiratory system MP:0005388 9.02 BRAF CD163 CD207 F13A1 LYZ

Drugs & Therapeutics for Non-Langerhans-Cell Histiocytosis

Drugs for Non-Langerhans-Cell Histiocytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 145)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 1177-87-3
2
leucovorin Approved Phase 3,Phase 2,Not Applicable 58-05-9 6006 143
3
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2 50-23-7 5754
4
Methotrexate Approved Phase 3,Phase 2,Not Applicable 59-05-2, 1959-05-2 126941
5
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 55-98-1 2478
6
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Not Applicable 6055-19-2, 50-18-0 2907
7
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
8
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
9
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 50-02-2 5743
10
Etoposide Approved Phase 3,Phase 2,Not Applicable 33419-42-0 36462
11
Hydrocortisone acetate Approved, Vet_approved Phase 3,Phase 2 50-03-3
12
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
13
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2,Phase 1,Not Applicable 2921-57-5
14
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
15
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
16
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 302-25-0
17
Miglustat Approved Phase 3,Phase 2,Phase 1 72599-27-0 51634
18
Pegaspargase Approved, Investigational Phase 3 130167-69-0
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Not Applicable 59-30-3 6037
20
Doxil Approved June 1999 Phase 3,Phase 2 31703
21
Prednisolone hemisuccinate Experimental Phase 3,Phase 2,Phase 1,Not Applicable 2920-86-7
22
1-Deoxynojirimycin Experimental, Investigational Phase 3,Phase 2 19130-96-2 1374
23 Antitubercular Agents Phase 3,Phase 2
24 BB 1101 Phase 3,Phase 2,Not Applicable
25 Hydrocortisone 17-butyrate 21-propionate Phase 3,Phase 2
26 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Not Applicable
27 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1,Not Applicable
28 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
29 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
30 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
31 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
32 Antilymphocyte Serum Phase 3,Phase 2,Phase 1,Not Applicable
33 Hydrocortisone-17-butyrate Phase 3,Phase 2
34 Calcineurin Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
35 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1,Not Applicable
36 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
37 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
38 Antifungal Agents Phase 3,Phase 2,Phase 1,Not Applicable
39 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
40 Antiemetics Phase 3,Phase 2,Phase 1,Not Applicable
41 Vitamin B9 Phase 3,Phase 2,Not Applicable
42 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
43 Vitamin B Complex Phase 3,Phase 2,Not Applicable
44 Etoposide phosphate Phase 3,Phase 2,Not Applicable
45 Folate Phase 3,Phase 2,Not Applicable
46 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
47 Folic Acid Antagonists Phase 3,Phase 2,Not Applicable
48 Gastrointestinal Agents Phase 3,Phase 2,Phase 1,Not Applicable
49 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
50 glucocorticoids Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 91)
# Name Status NCT ID Phase Drugs
1 Splenectomy as a Treatment for Patient With Relapsed Haemophagocytic Lymphohistiocytosis of Unknown Etiology Unknown status NCT02862054 Phase 2, Phase 3
2 Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis Unknown status NCT00334672 Phase 3 busulfan;cyclophosphamide;cyclosporine;dexamethasone;etoposide;methotrexate;mycophenolate mofetil;therapeutic hydrocortisone
3 Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004 Completed NCT00426101 Phase 3 Dexamethasone;Etoposide;Cyclosporin
4 Application of Miglustat in Patients With Niemann-Pick Type C Completed NCT01760564 Phase 3 Miglustat
5 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
6 DEP-Ru Regimen as a Salvage Therapy for HLH Recruiting NCT03533790 Phase 3 DEP-Ru
7 Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis Recruiting NCT03312751 Phase 3 Emapalumab
8 L-DEP as an Initial Treatment for EBV-HLH Recruiting NCT02912702 Phase 3 Pegaspargase;doxorubicin hydrochloride liposome injection;etoposide;methylprednisolone;Etoposide;dexamethasone
9 L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis Recruiting NCT02631109 Phase 3 Pegaspargase;doxorubicin;etoposide;methylprednisolone
10 A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis Recruiting NCT01818492 Phase 2, Phase 3
11 Arimoclomol Prospective Study in Patients Diagnosed With NiemannPick Disease Type C Active, not recruiting NCT02612129 Phase 2, Phase 3 arimoclomol;Placebo
12 Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) to Treat Niemann-Pick Type C1 (NPC1) Disease Active, not recruiting NCT02534844 Phase 2, Phase 3 VTS-270;Sham Procedure Control
13 Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency Active, not recruiting NCT02004691 Phase 2, Phase 3 placebo (saline);GZ402665
14 Etoposide in the First-line Treatment of Adult EBV-HLH Not yet recruiting NCT03742115 Phase 3 Etoposide;Dexamethasone;Etoposide;IVIG
15 T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders Terminated NCT00176826 Phase 2, Phase 3 Myeloablative conditioning regimen
16 Trial of DA-EPOCH Regimen for NHL With HLH Unknown status NCT01818908 Phase 2 DA-EPOCH
17 Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease Completed NCT02281760 Phase 2 Dabrafenib Mesylate;Trametinib Dimethyl Sulfoxide
18 Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis Completed NCT01104025 Phase 2 ATG, rabbit;Etoposide;Methotrexate;hydrocortisone;Dexamethasone
19 Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 Completed NCT02124083 Phase 1, Phase 2 Vorinostat
20 Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204) Completed NCT01998633 Phase 2
21 Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine Completed NCT00975689 Phase 1, Phase 2 N-Acetyl Cysteine
22 Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Completed NCT00730314 Phase 1, Phase 2
23 Miglustat in Niemann-Pick Type C Disease Completed NCT00517153 Phase 2 miglustat
24 Stem Cell Transplant for Immunologic or Histiocytic Disorders Completed NCT00176865 Phase 2 Fludarabine;Melphalan;Anti-thymocyte globulin (ATG);Campath 1H;Cyclosporin A;Mycophenolate mofetil;Intravenous immunoglobulin (IVIG)
25 Ruxolitinib Combined With Dexamethasone for HLH Recruiting NCT03795909 Phase 1, Phase 2 Ruxolitinib;Dexamethasone
26 Treatment of Familiar Lymphohistiocytosis Recruiting NCT02472054 Phase 1, Phase 2 Alemtuzumab;Methyl Prednisolone (MP);Cyclosporin A (CSA)
27 Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis Recruiting NCT02385110 Phase 2 Alemtuzumab;Etoposide;Dexamethasone;Methotrexate;Tocilizumab
28 Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH) Recruiting NCT02007239 Phase 2 tocilizumab
29 A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome Recruiting NCT02400463 Phase 2 Ruxolitinib
30 Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation Recruiting NCT03513328 Phase 1, Phase 2 Thiotepa--single daily dose;Thiotepa--escalated dose
31 Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C Recruiting NCT03471143 Phase 1, Phase 2 2-Hydroxypropyl-Beta-Cyclodextrin
32 A Study to Investigate the Safety and Efficacy of an Anti-IFN-gamma mAb in Children With Systemic Juvenile Idiopathic Arthritis (sJIA) Developing Macrophage Activation Syndrome/ Secondary Hemophagocytic Lymphohistiocytosis (MAS/sHLH) Recruiting NCT03311854 Phase 2 NI-0501
33 Study of Lithium Carbonate to Treat Niemann-Pick Type C1 Disease Recruiting NCT03201627 Phase 1, Phase 2 Lithium Carbonate
34 Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;Palbociclib;PI3K/mTOR Inhibitor LY3023414;Selumetinib Sulfate;Tazemetostat;Ulixertinib;Vemurafenib
35 Study of Pharmacokinetics and Preliminary Efficacy in Patients With Niemann-Pick C1 Recruiting NCT02912793 Phase 1, Phase 2 Hydroxypropyl-beta-cyclodextrin
36 Immune Disorder HSCT Protocol Recruiting NCT01821781 Phase 2 Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
37 T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts Recruiting NCT00368355 Phase 2 Ara-C;Cyclophosphamide
38 A Study of Lenalidomide for Adult Histiocyte Disorders Active, not recruiting NCT02523040 Phase 2 Lenalidomide
39 Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency Active, not recruiting NCT02292654 Phase 1, Phase 2 Olipudase alfa
40 Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders Active, not recruiting NCT01372228 Phase 1, Phase 2
41 A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency Enrolling by invitation NCT02004704 Phase 2 GZ402665
42 Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations Not yet recruiting NCT03794297 Phase 2 Dabrafenib Mesylate;Trametinib Dimethyl Sulfoxide
43 N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC) Not yet recruiting NCT03759639 Phase 2 IB1001
44 Safety and Tolerability Study of VTS-270 in Pediatric Participants With Niemann-Pick Type C (NPC) Disease Not yet recruiting NCT03687476 Phase 2 VTS-270
45 Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease Terminated NCT01727206 Phase 2 Tocilizumab
46 Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism Terminated NCT00668564 Phase 2 Cyclophosphamide;Campath-1H;Busulfan
47 Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease Completed NCT01747135 Phase 1 VTS-270
48 Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients Completed NCT01722526 Phase 1 Recombinant human acid sphingomyelinase
49 Saccadic Eye Movements in Patients With Niemann-Pick Type C Disease Completed NCT00316498 Phase 1 OGT918
50 Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1) Recruiting NCT02939547 Phase 1 Hydroxypropyl-beta-cyclodextrin

Search NIH Clinical Center for Non-Langerhans-Cell Histiocytosis

Cochrane evidence based reviews: histiocytosis, non-langerhans-cell

Genetic Tests for Non-Langerhans-Cell Histiocytosis

Anatomical Context for Non-Langerhans-Cell Histiocytosis

MalaCards organs/tissues related to Non-Langerhans-Cell Histiocytosis:

41
Pituitary, Myeloid, Smooth Muscle

Publications for Non-Langerhans-Cell Histiocytosis

Articles related to Non-Langerhans-Cell Histiocytosis:

(show all 27)
# Title Authors Year
1
A Rare Case of Erdheim-Chester Disease (Non-Langerhans Cell Histiocytosis) with Concurrent Langerhans Cell Histiocytosis: A Diagnostic and Therapeutic Challenge. ( 29888013 )
2018
2
High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. ( 28679734 )
2017
3
Non-Langerhans cell histiocytosis. ( 26739442 )
2016
4
Spontaneous regression of infantile dural-based non-Langerhans cell histiocytosis after surgery: case report. ( 25634822 )
2015
5
[Erdheim-Chester disease and Rosai-Dorfman disease: Pathological, radiological and clinical features of adult non-Langerhans cell histiocytosis]. ( 26305142 )
2015
6
Suprasellar non-Langerhans cell histiocytosis (Erdheim-Chester disease)--a case report. ( 23465991 )
2013
7
Retinal manifestations in a patient with xanthoma disseminatum (non-langerhans cell histiocytosis). ( 21484660 )
2011
8
Rare case of infratentorial non-Langerhans cell histiocytosis with lethal outcome presenting multiple diagnostic difficulties. ( 22025140 )
2011
9
Non-Langerhans cell histiocytosis with isolated CNS involvement: an unusual variant of Erdheim-Chester disease. ( 20337948 )
2010
10
Intracranial non-Langerhans cell histiocytosis presenting as an isolated intraparenchymal lesion. ( 20635081 )
2010
11
Fibroblastic rheumatism: fibromatosis rather than non-Langerhans cell histiocytosis. ( 19615014 )
2010
12
Endolymphatic non-langerhans cell histiocytosis of the larynx: report of an uncommon disease manifestation. ( 20463609 )
2010
13
Non-Langerhans cell histiocytosis in a child with Kawasaki disease. ( 21686403 )
2009
14
Diffuse xanthogranulomatous dermatitis and systemic Langerhans cell histiocytosis: A novel case that demonstrates bridging between non-Langerhans cell histiocytosis and Langerhans cell histiocytosis. ( 19022530 )
2009
15
Cerebral non-Langerhans cell histiocytosis in a 17-year-old patient with a headache: case report. ( 19363626 )
2009
16
Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. ( 16020507 )
2005
17
[Erdheim-Chester disease: a non-Langerhans cell histiocytosis. A clinical-case and review of the literature]. ( 15344569 )
2004
18
Progressive histiocytosis: description of a case of slow-course non-Langerhans cell histiocytosis. ( 12399681 )
2002
19
Problems in differential diagnosis of non Langerhans cell histiocytosis with pituitary involvement: case report and review of literature. ( 12665654 )
2002
20
A child with both Langerhans and non-Langerhans cell histiocytosis. ( 12383099 )
2002
21
Primary cerebral non-Langerhans cell histiocytosis: MRI and differential diagnosis. ( 12221448 )
2002
22
Benign cephalic histiocytosis progressing into juvenile xanthogranuloma: a non-Langerhans cell histiocytosis transforming under the influence of a virus? ( 10698221 )
2000
23
Non-Langerhans cell histiocytosis associated with lymphocyte-predominant Hodgkin's disease. ( 10564322 )
1999
24
Generalized non-Langerhans cell histiocytosis: four cases illustrate a spectrum of disease. ( 7737766 )
1995
25
An unusual case of non-Langerhans cell histiocytosis. ( 8294600 )
1994
26
A unique non-Langerhans cell histiocytosis with some features of generalized eruptive histiocytoma. ( 8034797 )
1994
27
Congenital self-healing non-Langerhans cell histiocytosis. ( 3058480 )
1988

Variations for Non-Langerhans-Cell Histiocytosis

Expression for Non-Langerhans-Cell Histiocytosis

Search GEO for disease gene expression data for Non-Langerhans-Cell Histiocytosis.

Pathways for Non-Langerhans-Cell Histiocytosis

Pathways related to Non-Langerhans-Cell Histiocytosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.02 CD163 CD207
2 10.81 ACTC1 DES
3 10.47 CD163 IL1RN

GO Terms for Non-Langerhans-Cell Histiocytosis

Biological processes related to Non-Langerhans-Cell Histiocytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.33 CD163 IL1RN LYZ
2 response to drug GO:0042493 9.13 ACTC1 IL1RN SST
3 muscle filament sliding GO:0030049 8.62 ACTC1 DES

Sources for Non-Langerhans-Cell Histiocytosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....